Literature DB >> 19389440

Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector.

John P Miller1, Yongzhi Geng, Hwee L Ng, Otto O Yang, Paul Krogstad.   

Abstract

Enteroviruses elicit protective mucosal immune responses that could be harnessed as part of a strategy to prevent sexual transmission of the human immunodeficiency virus-1 (HIV-1). We report the construction of replication-competent recombinant vectors of coxsackievirus B3 (CVB3) that express one or more portions of the HIV-1 Gag protein. Vectors containing the capsid domain of Gag were initially genetically unstable with protein expression lost after brief passage in tissue culture. Codon modification to increase the G/C content of the HIV-1 capsid sequence resulted in enhanced genetic stability of CVB3 vectors during in vitro passage. Cells infected with a vector expressing the matrix (MA) subunit of the HIV-1 Gag protein were susceptible to lysis by CD8 T cell clones specific for the SL9 epitope found within MA. These studies suggest that CVB3 vectors may be useful as vaccine vector candidates, if hurdles in class I antigen presentation and stability can be overcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389440      PMCID: PMC2745320          DOI: 10.1016/j.vaccine.2009.04.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

1.  A therapeutic HIV vaccine using coxsackie-HIV recombinants: a possible new strategy.

Authors:  S S Halim; D N Collins; A I Ramsingh
Journal:  AIDS Res Hum Retroviruses       Date:  2000-10-10       Impact factor: 2.205

Review 2.  Inhibiting sexual transmission of HIV-1 infection.

Authors:  Robin J Shattock; John P Moore
Journal:  Nat Rev Microbiol       Date:  2003-10       Impact factor: 60.633

3.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.

Authors:  S Crotty; C J Miller; B L Lohman; M R Neagu; L Compton; D Lu; F X Lü; L Fritts; J D Lifson; R Andino
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system.

Authors:  Sang-Gu Lee; Dae-You Kim; Byung-Hwa Hyun; Yong-Soo Bae
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro.

Authors:  Ralph Feuer; Ignacio Mena; Robb Pagarigan; Mark K Slifka; J Lindsay Whitton
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.

Authors:  Karina Yusim; Can Kesmir; Brian Gaschen; Marylyn M Addo; Marcus Altfeld; Søren Brunak; Alexandre Chigaev; Vincent Detours; Bette T Korber
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.

Authors:  Scott G Hansen; Cassandra Vieville; Nathan Whizin; Lia Coyne-Johnson; Don C Siess; Derek D Drummond; Alfred W Legasse; Michael K Axthelm; Kelli Oswald; Charles M Trubey; Michael Piatak; Jeffrey D Lifson; Jay A Nelson; Michael A Jarvis; Louis J Picker
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

9.  Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.

Authors:  Peter A Anton; F Javier Ibarrondo; W John Boscardin; Ying Zhou; Elissa J Schwartz; Hwee L Ng; Mary Ann Hausner; Roger Shih; Julie Elliott; Patricia M Hultin; Lance E Hultin; Charles Price; Marie Fuerst; Amy Adler; Johnson T Wong; Otto O Yang; Beth D Jamieson
Journal:  Vaccine       Date:  2008-06-17       Impact factor: 3.641

10.  Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses.

Authors:  Ayub Ali; Beth D Jamieson; Otto O Yang
Journal:  J Virol Methods       Date:  2003-06-30       Impact factor: 2.014

View more
  8 in total

1.  Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses.

Authors:  Jun Zuo; Steve Kye; Kevin K Quinn; Paige Cooper; Robert Damoiseaux; Paul Krogstad
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 2.  Emergency Services of Viral RNAs: Repair and Remodeling.

Authors:  Vadim I Agol; Anatoly P Gmyl
Journal:  Microbiol Mol Biol Rev       Date:  2018-03-14       Impact factor: 11.056

Review 3.  Type B coxsackieviruses and their interactions with the innate and adaptive immune systems.

Authors:  Christopher C Kemball; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

Review 4.  Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

5.  Fluoxetine is a potent inhibitor of coxsackievirus replication.

Authors:  Jun Zuo; Kevin K Quinn; Steve Kye; Paige Cooper; Robert Damoiseaux; Paul Krogstad
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

6.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

Review 7.  Therapeutic Use of Native and Recombinant Enteroviruses.

Authors:  Jani Ylä-Pelto; Lav Tripathi; Petri Susi
Journal:  Viruses       Date:  2016-02-23       Impact factor: 5.048

8.  Complete Genome Sequence of Coxsackievirus B1 Isolated during Case Outbreaks in 2007 in the United States.

Authors:  Kevin K Quinn; Susan K Wollersheim; Paul Krogstad
Journal:  Genome Announc       Date:  2014-07-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.